voxelotor Inhibitor

MBS5758473 is an inhibitor targeting voxelotor. voxelotor is an inhibitor of sickle hemoglobin (HbS)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease[J]. Hematology Reports, 2018, 10(2).
Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease[J]. Hematology Reports, 2018, 10(2).
Hutchaleelaha A, Patel M, Washington C, et al. Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease[J]. British Journal of Clinical Pharmacology, 2019.
Hutchaleelaha A, Patel M, Washington C, et al. Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease[J]. British Journal of Clinical Pharmacology, 2019.
Metcalf B, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett. 2017 Jan 23;8(3):321-326.

Small volumes of voxelotor, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.